IDEXX Laboratories, Inc.(IDXX)Earnings, Financials & Key Ratios

IDXX•NASDAQ

$562.97

$44.83B mkt cap·43.0× P/E·Price updated May 6, 2026

SectorHealthcare IndustryDiagnostics & Research Sub-IndustryFood, Water and Veterinary Diagnostics

AboutIDEXX Laboratories, Inc. develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through CAG; Water Quality Products; LPD; and Other segments. It provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services for biomedical research community. The company also offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; and point-of-care electrolytes and blood gas analyzers and SARS-CoV-2 RT-PCR that are used in the human point-of-care medical diagnostics market; in-clinic chemistry, blood and urine chemistry, hematology, and SediVue Dx analyzers; SNAP rapid assays test kits. In addition, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; veterinary software and services for independent veterinary clinics and corporate groups. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.Show more

Revenue$4.3B+10.4%
EBITDA$1.47B+16.5%
Net Income$1.06B+19.3%
EPS (Diluted)13.08+22.6%
Gross Margin61.8%+1.2%
EBITDA Margin34.08%+5.5%
Operating Margin31.6%+9.2%
Net Margin24.62%+8.1%
ROE66.2%+14.8%
ROIC42.53%+10.4%
Debt/Equity0.67+8.5%
Interest Coverage35.61-2.6%

Analysis→Technical→

IDXX Key Insights

IDEXX Laboratories, Inc. (IDXX) fundamental analysis — strengths, weaknesses & financial health based on data analysis

✓Strengths

✓Excellent 3Y average ROE of 68.2%
✓Strong Piotroski F-Score: 7/9
✓FCF machine: 24.5% free cash flow margin
✓Share count reduced 3.1% through buybacks
✓Healthy 5Y average net margin of 22.8%
✓Efficient asset utilization: 1.3x turnover

✗Weaknesses

✗Expensive at 28.3x book value

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

IDXX Price & Volume

IDEXX Laboratories, Inc. (IDXX) stock price & volume — 10-year historical chart

Loading chart...

IDXX Growth Metrics

IDEXX Laboratories, Inc. (IDXX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years10.39%

5 Years9.72%

3 Years8.52%

TTM13.08%

Profit CAGR

10 Years18.62%

5 Years12.74%

3 Years15.98%

TTM22.38%

EPS CAGR

10 Years20.36%

5 Years14.28%

3 Years17.66%

TTM-6.56%

Return on Capital

10 Years57.6%

5 Years56.03%

3 Years56.22%

Last Year61.44%

IDXX Recent Earnings

IDEXX Laboratories, Inc. (IDXX) EPS & revenue vs analyst estimates — last 4 quarters

Full history →

●Beat EPS 12/12 qtrs (100%)●Beat Revenue 8/12 qtrs (67%)

Q2 2026Latest

May 5, 2026

EPS

$3.47

Est $3.41

+1.8%

Revenue

$1.1B

Est $1.1B

+2.0%

Q1 2026

Feb 2, 2026

EPS

$3.08

Est $2.93

+5.1%

Revenue

$1.1B

Est $1.1B

+1.7%

Q4 2025

Nov 3, 2025

EPS

$3.40

Est $3.14

+8.3%

Revenue

$1.1B

Est $1.1B

+3.0%

Q3 2025

Aug 4, 2025

EPS

$3.63

Est $3.28

+10.7%

Revenue

$1.1B

Est $1.1B

+4.4%

Quarter	Date	EPS (Act vs Est)	Revenue (Act vs Est)
Q2 2026Latest	May 5, 2026	$3.47vs $3.41+1.8%	$1.1Bvs $1.1B+2.0%
Q1 2026	Feb 2, 2026	$3.08vs $2.93+5.1%	$1.1Bvs $1.1B+1.7%
Q4 2025	Nov 3, 2025	$3.40vs $3.14+8.3%	$1.1Bvs $1.1B+3.0%
Q3 2025	Aug 4, 2025	$3.63vs $3.28+10.7%	$1.1Bvs $1.1B+4.4%

Based on last 12 quarters of dataView full earnings history →

Company	Market Cap	Stock Price	P/E Ratio (TTM)	Revenue Growth 1Y	Net Margin	Return on Equity (ROE)	FCF Yield	Debt / Equity
ZTSZoetis Inc.Direct Competitor	47.51B	112.54	18.69	2.28%	28.23%	58.23%	4.81%	2.85
HSICHenry Schein, Inc.Direct Competitor	8.53B	74.37	22.74	4.03%	3.02%	8.24%	6.71%	0.77
ELANElanco Animal Health IncorporatedDirect Competitor	11.43B	23.00	-48.94	6.22%	-4.92%	-3.54%	2.48%	0.61
ANIPANI Pharmaceuticals, Inc.Product Competitor	1.8B	84.63	25.49	43.78%	8.87%	14.49%	10.31%	0.60
NEOGNeogen CorporationProduct Competitor	2.02B	9.27	-1.84	-3.2%	-68.47%	-28.64%		0.44
CHWYChewy, Inc.Product Competitor	10.17B	24.54	26.97	6.4%	1.22%	38.76%	4.45%	1.92
DHRDanaher CorporationSupply Chain	123.6B	174.63	34.65	2.9%	14.89%	7.06%	4.26%	0.35
BIOBio-Rad Laboratories, Inc.Supply Chain	6.94B	257.12	9.23	0.65%	6.52%	2.4%	5.4%	0.21

Compare IDXX vs Peers

IDEXX Laboratories, Inc. (IDXX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs ZTS

Most directly comparable listed peer for IDXX.

Scale Benchmark

vs TMO

Larger-name benchmark to compare IDXX against a more recognizable public peer.

Peer Set

Compare Top 5

vs ZTS, HSIC, ELAN, ANIP

IDXX Income Statement

IDEXX Laboratories, Inc. (IDXX) annual income statement — 10-year revenue, gross profit & net income history

10Y historyFree accessUpdated daily

Line item	Dec'17	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23	Dec'24	Dec'25	TTM
Sales/Revenue	1.97B	2.21B	2.41B	2.71B	3.22B	3.37B	3.66B	3.9B	4.3B	4.45B
Revenue Growth %	10.91%	12.4%	8.75%	12.45%	18.79%	4.73%	8.72%	6.46%	10.42%	13.08%
Cost of Goods Sold	871.68M	971.7M	1.04B	1.14B	1.33B	1.36B	1.47B	1.52B	1.64B	1.69B
COGS % of Revenue	44.27%	43.9%	43.27%	41.96%	41.24%	40.48%	40.18%	38.96%	38.2%	-
Gross Profit	1.1B▲ 0%	1.24B▲ 13.1%	1.37B▲ 10.0%	1.57B▲ 15.0%	1.89B▲ 20.3%	2B▲ 6.1%	2.19B▲ 9.3%	2.38B▲ 8.6%	2.66B▲ 11.8%	2.76B▲ 0%
Gross Margin %	55.73%	56.1%	56.73%	58.04%	58.76%	59.52%	59.82%	61.04%	61.8%	62.05%
Gross Profit Growth %	12.5%	13.14%	9.99%	15.05%	20.27%	6.08%	9.26%	8.63%	11.8%	-
Operating Expenses	684.35M	750.21M	812.7M	876.52M	957.4M	1.11B	1.09B	1.25B	1.3B	1.35B
OpEx % of Revenue	34.76%	33.9%	33.77%	32.38%	29.78%	32.83%	29.85%	32.09%	30.2%	-
Selling, General & Admin	575.17M	632.34M	679.51M	735.27M	796.39M	850.75M	901.89M	1.03B	1.05B	1.09B
SG&A % of Revenue	29.21%	28.57%	28.23%	27.17%	24.77%	25.26%	24.64%	26.45%	24.36%	-
Research & Development	109.18M	117.86M	133.19M	141.25M	161.01M	254.82M	190.95M	219.79M	251.21M	257.93M
R&D % of Revenue	5.54%	5.33%	5.53%	5.22%	5.01%	7.57%	5.22%	5.64%	5.84%	-
Other Operating Expenses	0	0	0	0	1.46M	2.2M	0	0	0	0
Operating Income	413.03M▲ 0%	491.33M▲ 19.0%	552.85M▲ 12.5%	694.52M▲ 25.6%	932.03M▲ 34.2%	898.76M▼ 3.6%	1.1B▲ 22.1%	1.13B▲ 2.8%	1.36B▲ 20.5%	1.41B▲ 0%
Operating Margin %	20.98%	22.2%	22.97%	25.66%	28.99%	26.69%	29.97%	28.95%	31.6%	31.63%
Operating Income Growth %	17.93%	18.96%	12.52%	25.63%	34.2%	-3.57%	22.07%	2.84%	20.53%	-
EBITDA	496.17M	574.51M	640.86M	790.52M	1.04B	1.01B	1.21B	1.26B	1.47B	1.52B
EBITDA Margin %	25.2%	25.96%	26.63%	29.21%	32.24%	30.01%	33.11%	32.28%	34.08%	34.12%
EBITDA Growth %	15.8%	15.79%	11.55%	23.35%	31.13%	-2.5%	19.92%	3.81%	16.55%	18.53%
D&A (Non-Cash Add-back)	83.14M	83.18M	88.01M	96M	104.6M	111.9M	114.91M	129.94M	106.46M	111.12M
EBIT	418.28M	492.49M	553.27M	695.11M	932.46M	899.83M	1.1B	1.14B	1.36B	1.05B
Net Interest Income	-31.97M	-33.59M	-30.63M	-32.54M	-29.37M	-38.79M	-35.95M	-18.51M	-35.84M	-30.7M
Interest Income	5.25M	1.15M	427K	586K	434K	1.06M	5.63M	12.7M	2.42M	1.79M
Interest Expense	37.23M	34.74M	31.05M	33.13M	29.81M	39.86M	41.58M	31.2M	38.27M	25.35M
Other Income/Expense	-31.97M	-33.59M	-30.63M	-32.54M	-29.37M	-38.79M	-35.95M	-18.51M	-35.84M	-36.54M
Pretax Income	381.06M▲ 0%	457.74M▲ 20.1%	522.22M▲ 14.1%	661.99M▲ 26.8%	902.65M▲ 36.4%	859.97M▼ 4.7%	1.06B▲ 23.4%	1.11B▲ 4.6%	1.32B▲ 19.3%	1.37B▲ 0%
Pretax Margin %	19.35%	20.68%	21.7%	24.46%	28.07%	25.54%	28.99%	28.48%	30.77%	30.8%
Income Tax	117.79M	80.69M	94.43M	79.85M	157.81M	180.88M	216.13M	221.96M	264.73M	274.31M
Effective Tax Rate %	30.91%	17.63%	18.08%	12.06%	17.48%	21.03%	20.37%	20%	19.99%	20.03%
Net Income	263.14M▲ 0%	377.03M▲ 43.3%	427.72M▲ 13.4%	581.78M▲ 36.0%	744.85M▲ 28.0%	679.09M▼ 8.8%	845.04M▲ 24.4%	887.87M▲ 5.1%	1.06B▲ 19.3%	1.1B▲ 0%
Net Margin %	13.36%	17.04%	17.77%	21.49%	23.17%	20.17%	23.08%	22.78%	24.62%	24.63%
Net Income Growth %	18.51%	43.28%	13.44%	36.02%	28.03%	-8.83%	24.44%	5.07%	19.33%	22.38%
Net Income (Continuing)	263.27M	377.05M	427.79M	582.13M	744.84M	679.09M	845.04M	887.87M	1.06B	816.79M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	264K	280K	352K	707K	0	0	0	0	0	0
EPS (Diluted)	2.94▲ 0%	4.26▲ 44.9%	4.89▲ 14.8%	6.71▲ 37.2%	8.60▲ 28.2%	8.03▼ 6.6%	10.06▲ 25.3%	10.67▲ 6.1%	13.08▲ 22.6%	-▲ 0%
EPS Growth %	20.49%	44.9%	14.79%	37.22%	28.17%	-6.63%	25.28%	6.06%	22.59%	-6.56%
EPS (Basic)	3.00	4.34	4.97	6.82	8.74	8.12	10.17	10.77	13.17	-
Diluted Shares Outstanding	89.57M	88.47M	87.54M	86.72M	86.57M	84.6M	83.98M	83.25M	80.67M	0
Basic Shares Outstanding	87.77M	86.86M	86.11M	85.34M	85.2M	83.62M	83.07M	82.47M	80.1M	0
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

IDXX Balance Sheet

IDEXX Laboratories, Inc. (IDXX) balance sheet — assets, liabilities & shareholders' equity

Line item	Dec'17	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23	Dec'24	Dec'25	TTM
Total Current Assets	971.99M	654.17M	679.64M	1.06B	955.65M	1.1B	1.5B	1.4B	1.34B	1.45B
Cash & Short-Term Investments	471.93M	123.79M	90.33M	383.93M	144.45M	112.55M	453.93M	288.27M	180.07M	200.53M
Cash Only	187.68M	123.79M	90.33M	383.93M	144.45M	112.55M	453.93M	288.27M	180.07M	200.53M
Short-Term Investments	284.25M	0	0	0	0	0	0	0	0	0
Accounts Receivable	270.07M	258.52M	307.49M	374.74M	425.58M	490.9M	529.53M	561.32M	693.19M	603.54M
Days Sales Outstanding	50.06	42.63	46.63	50.53	48.31	53.21	52.79	52.57	58.79	54.9
Inventory	164.32M	173.3M	195.02M	209.87M	269.03M	367.82M	380.28M	381.88M	377.76M	382.4M
Days Inventory Outstanding	68.81	65.1	68.35	67.46	74.06	98.5	94.36	91.79	83.86	83.52
Other Current Assets	101.14M	54.14M	54.81M	59.64M	74.59M	88.46M	83.14M	109.81M	31.35M	267.6M
Total Non-Current Assets	741.43M	883.18M	1.15B	1.23B	1.48B	1.65B	1.76B	1.89B	2.01B	1.93B
Property, Plant & Equipment	379.1M	437.27M	614.45M	646.34M	692.77M	768.09M	817.68M	829.25M	870.61M	740.38M
Fixed Asset Turnover	5.19x	5.06x	3.92x	4.19x	4.64x	4.38x	4.48x	4.70x	4.94x	5.31x
Goodwill	199.87M	214.49M	239.72M	243.35M	359.35M	361.8M	365.96M	405.1M	414M	412.1M
Intangible Assets	43.85M	41.83M	58.47M	52.54M	99.03M	97.67M	84.5M	111.68M	109.84M	104.75M
Long-Term Investments	9.95M	10.89M	13.66M	12.06M	18.6M	55.5M	56.19M	57.72M	297.09M	632.04M
Other Non-Current Assets	100.97M	170.22M	218.44M	245.98M	287.02M	307.01M	332.98M	364.17M	291.08M	1.64B
Total Assets	1.71B▲ 0%	1.54B▼ 10.3%	1.83B▲ 19.2%	2.29B▲ 25.2%	2.44B▲ 6.2%	2.75B▲ 12.7%	3.26B▲ 18.7%	3.29B▲ 1.0%	3.35B▲ 1.7%	3.39B▲ 0%
Asset Turnover	1.15x	1.44x	1.31x	1.18x	1.32x	1.23x	1.12x	1.18x	1.28x	1.32x
Asset Growth %	11.94%	-10.28%	19.2%	25.22%	6.22%	12.7%	18.68%	1.03%	1.74%	5.7%
Total Current Liabilities	1B	770.44M	725.34M	582.76M	763.58M	1.24B	951.55M	1.07B	1.15B	1.3B
Accounts Payable	66.97M	69.53M	72.17M	74.56M	116.14M	110.22M	110.64M	114.21M	110.41M	129.97M
Days Payables Outstanding	28.04	26.12	25.3	23.96	31.97	29.52	27.45	27.45	24.51	25.92
Short-Term Debt	655M	398.94M	288.76M	49.99M	148.5M	653.98M	325M	417.79M	500.07M	680M
Deferred Revenue (Current)	29.18M	41.29M	41.46M	42.57M	40.03M	37.94M	37.2M	33.8M	35.26M	143.61M
Other Current Liabilities	102.94M	109.49M	127.17M	167.65M	182.93M	142.99M	174.38M	174.58M	201.96M	583.53M
Current Ratio	0.97x	0.85x	0.94x	1.82x	1.25x	0.89x	1.57x	1.31x	1.17x	1.17x
Quick Ratio	0.80x	0.62x	0.67x	1.46x	0.90x	0.59x	1.17x	0.95x	0.84x	0.84x
Cash Conversion Cycle	90.83	81.61	89.69	94.03	90.4	122.2	119.7	116.9	118.14	112.51
Total Non-Current Liabilities	762.69M	776.14M	929.31M	1.08B	983.63M	902.23M	823.85M	630.21M	596.56M	143.34M
Long-Term Debt	606.08M	601.35M	698.91M	858.49M	775.21M	694.39M	622.88M	449.79M	475.99M	98.75M
Capital Lease Obligations	0	0	67.47M	77.04M	87.38M	101.24M	99.67M	97.84M	101.15M	315.28M
Deferred Tax Liabilities	25.35M	29.27M	33.02M	11.71M	8.94M	8.15M	7.24M	11.31M	31.86M	82.27M
Other Non-Current Liabilities	95.72M	84.83M	81.16M	85.6M	70.94M	67.59M	65.53M	44.34M	-44.62M	69.78M
Total Liabilities	1.77B	1.55B	1.65B	1.66B	1.75B	2.14B	1.78B	1.7B	1.75B	529.54M
Total Debt	1.26B	1B	1.07B	1B	1.03B	1.47B	1.07B	986.95M	1.08B	680M
Net Debt	1.07B	876.49M	980.1M	619.32M	886.55M	1.36B	613.42M	698.68M	897.14M	479.47M
Debt / Equity	-	-	6.02x	1.59x	1.49x	2.41x	0.72x	0.62x	0.67x	0.67x
Debt / EBITDA	2.54x	1.74x	1.67x	1.27x	0.99x	1.45x	0.88x	0.78x	0.73x	0.45x
Net Debt / EBITDA	2.16x	1.53x	1.53x	0.78x	0.86x	1.34x	0.51x	0.56x	0.61x	0.61x
Interest Coverage	11.24x	14.17x	17.82x	20.98x	31.28x	22.58x	26.52x	36.57x	35.61x	41.29x
Total Equity	-53.84M▲ 0%	-9.23M▲ 82.9%	177.82M▲ 2026.0%	632.79M▲ 255.9%	689.99M▲ 9.0%	608.74M▼ 11.8%	1.48B▲ 143.9%	1.6B▲ 7.5%	1.61B▲ 0.6%	1.56B▲ 0%
Equity Growth %	50.24%	82.85%	2025.97%	255.85%	9.04%	-11.78%	143.87%	7.46%	0.63%	-3.1%
Book Value per Share	-0.60	-0.10	2.03	7.30	7.97	7.20	17.68	19.16	19.90	19.90
Total Shareholders' Equity	-54.11M	-9.51M	177.47M	632.09M	689.99M	608.74M	1.48B	1.6B	1.61B	1.56B
Common Stock	10.43M	10.51M	10.57M	10.65M	10.69M	10.72M	10.75M	10.78M	10.84M	10.85M
Retained Earnings	803.54M	1.17B	1.6B	2.18B	2.92B	3.6B	4.44B	5.33B	6.39B	6.67B
Treasury Stock	-1.91B	-2.29B	-2.6B	-2.8B	-3.57B	-4.39B	-4.47B	-5.33B	-6.56B	0
Accumulated OCI	-36.47M	-41.79M	-46.18M	-53.62M	-53.48M	-77.8M	-71.21M	-93.64M	-62.75M	-64.94M
Minority Interest	264K	280K	352K	707K	0	0	0	0	0	0

IDXX Cash Flow Statement

IDEXX Laboratories, Inc. (IDXX) cash flow — operating, investing & free cash flow history

Line item	Dec'17	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23	Dec'24	Dec'25	TTM
Cash from Operations	373.28M	400.08M	459.16M	648.06M	755.55M	542.98M	906.51M	929M	1.18B	1.18B
Operating CF Margin %	18.96%	18.08%	19.08%	23.94%	23.5%	16.13%	24.76%	23.84%	27.37%	-
Operating CF Growth %	11.57%	7.18%	14.77%	41.14%	16.59%	-28.13%	66.95%	2.48%	26.81%	103.85%
Net Income	263.27M	377.05M	427.79M	582.13M	744.84M	679.09M	845.04M	887.87M	1.06B	1.1B
Depreciation & Amortization	83.14M	83.18M	88.01M	96M	104.6M	111.9M	114.91M	129.94M	145.18M	4.66M
Stock-Based Compensation	23.52M	25.16M	39.28M	30.95M	37.76M	49.77M	59.74M	60.3M	0	-14.62M
Deferred Taxes	-7.92M	1.21M	6.16M	-38.08M	-3.38M	-35.06M	-48.31M	-24.19M	131.2M	27.58M
Other Non-Cash Items	2.89M	5.13M	2.88M	8.83M	9.25M	10.82M	7.56M	8.34M	69.73M	15.83M
Working Capital Changes	8.38M	-91.64M	-104.97M	-31.76M	-137.52M	-273.53M	-72.43M	-133.24M	-227.51M	77.67M
Change in Receivables	-24.92M	-18.4M	-22.47M	-60.72M	-33.14M	-41.4M	-53.87M	-28.28M	-68.72M	59.1M
Change in Inventory	-19.06M	-25.62M	-37.31M	-18.89M	-52.92M	-121.73M	-28.65M	-28M	-789K	-750K
Change in Payables	1.39M	-166K	1.96M	981K	11.23M	3.47M	-557K	8.09M	-8.57M	4.53M
Cash from Investing	-138.69M	138.6M	-205.53M	-109.38M	-292.97M	-195.35M	-125.25M	-207.06M	-136.24M	-140.17M
Capital Expenditures	-76.7M	-122.94M	-155.22M	-107.63M	-119.55M	-148.84M	-133.63M	-120.92M	-138.23M	-126.83M
CapEx % of Revenue	3.9%	5.55%	6.45%	3.98%	3.72%	4.42%	3.65%	3.1%	3.21%	-
Acquisitions	-14.58M	-22.5M	-50.3M	-1.75M	-173.42M	-46.51M	0	-77.7M	0	0
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	0	0	0	0	-46.51M	8.38M	-10M	2.74M	-13.34M
Cash from Financing	-208.02M	-597.8M	-286.41M	-248.42M	-697.41M	-370.94M	-442M	-878.07M	-1.16B	-1.04B
Debt Issued (Net)	44M	-256.04M	-10.28M	-94.65M	23.5M	430.5M	-404M	-75M	-30.39M	-99.89M
Equity Issued (Net)	-252.02M	-331.12M	-265.55M	-131.49M	-700.21M	-783.96M	-24.89M	-792.54M	-1.12B	-805.4M
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-290.64M	-369.32M	-301.66M	-182.81M	-746.78M	-819.71M	-71.92M	-837.03M	-1.22B	-1.17B
Other Financing	0	-10.64M	-10.43M	-22.28M	-20.7M	-17.04M	-13.11M	-10.53M	-7.24M	-137.05M
Net Change in Cash	32.77M▲ 0%	-63.88M▼ 294.9%	-33.47M▲ 47.6%	293.6M▲ 977.3%	-239.47M▼ 181.6%	-31.91M▲ 86.7%	341.39M▲ 1169.9%	-165.67M▼ 148.5%	-108.2M▲ 34.7%	36.56M▲ 0%
Free Cash Flow	296.57M▲ 0%	277.15M▼ 6.5%	303.93M▲ 9.7%	540.44M▲ 77.8%	636M▲ 17.7%	394.15M▼ 38.0%	772.88M▲ 96.1%	798.08M▲ 3.3%	1.05B▲ 32.0%	1.08B▲ 0%
FCF Margin %	15.06%	12.52%	12.63%	19.97%	19.78%	11.71%	21.11%	20.48%	24.48%	24.28%
FCF Growth %	9.93%	-6.55%	9.66%	77.81%	17.68%	-38.03%	96.09%	3.26%	31.99%	28.89%
FCF per Share	3.31	3.13	3.47	6.23	7.35	4.66	9.20	9.59	13.06	13.06
FCF Conversion (FCF/Net Income)	1.42x	1.06x	1.07x	1.11x	1.01x	0.80x	1.07x	1.05x	1.11x	0.99x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

IDXX Key Ratios

IDEXX Laboratories, Inc. (IDXX) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios

Metric	2017	2018	2019	2020	2021	2022	2023	2024	2025	TTM
Return on Equity (ROE)	-	-	507.4%	143.54%	112.62%	104.58%	80.74%	57.66%	66.2%	70.87%
Return on Invested Capital (ROIC)	31.6%	39.06%	40.95%	43.23%	49.42%	38.05%	40.49%	38.54%	42.53%	42.53%
Gross Margin	55.73%	56.1%	56.73%	58.04%	58.76%	59.52%	59.82%	61.04%	61.8%	62.05%
Net Margin	13.36%	17.04%	17.77%	21.49%	23.17%	20.17%	23.08%	22.78%	24.62%	24.63%
Debt / Equity	-	-	6.02x	1.59x	1.49x	2.41x	0.72x	0.62x	0.67x	0.67x
Interest Coverage	11.24x	14.17x	17.82x	20.98x	31.28x	22.58x	26.52x	36.57x	35.61x	41.29x
FCF Conversion	1.42x	1.06x	1.07x	1.11x	1.01x	0.80x	1.07x	1.05x	1.11x	0.99x
Revenue Growth	10.91%	12.4%	8.75%	12.45%	18.79%	4.73%	8.72%	6.46%	10.42%	13.08%

IDXX SEC Filings & Documents

IDEXX Laboratories, Inc. (IDXX) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

Material company update

May 5, 2026·SEC

Material company update

Mar 26, 2026·SEC

Material company update

Feb 13, 2026·SEC

10-K Annual Reports

FY 2026

Feb 20, 2026·SEC

FY 2025

Feb 21, 2025·SEC

FY 2024

Feb 22, 2024·SEC

10-Q Quarterly Reports

FY 2026

May 5, 2026·SEC

FY 2025

Nov 3, 2025·SEC

FY 2025

Aug 4, 2025·SEC

IDXX Frequently Asked Questions

IDEXX Laboratories, Inc. (IDXX) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials

IDEXX Laboratories, Inc. (IDXX) reported $4.45B in revenue for fiscal year 2025. This represents a 1561% increase from $267.7M in 1996.

IDEXX Laboratories, Inc. (IDXX) grew revenue by 10.4% over the past year. This is steady growth.

Yes, IDEXX Laboratories, Inc. (IDXX) is profitable, generating $1.10B in net income for fiscal year 2025 (24.6% net margin).

Dividend & Returns

IDEXX Laboratories, Inc. (IDXX) has a return on equity (ROE) of 66.2%. This is excellent, indicating efficient use of shareholder capital.

IDEXX Laboratories, Inc. (IDXX) generated $1.08B in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

Explore More IDXX

IDEXX Laboratories, Inc. (IDXX) financial analysis — history, returns, DCA and operating performance tools

Full IDXX Stock Analysis

Analyst verdict, bull/bear case, risk factors and peer comparison

→

Total Return Calculator

Historical returns with dividends reinvested

→

DCA Calculator

Dollar cost averaging vs lump sum

→

Dividend History

Yield, growth, payout safety & DRIP

→

Earnings History

EPS trends, net income & profitability

→

Price History

Long-term charts & historical price data

→

Revenue History

Sales growth patterns & revenue breakdown

→

Financial Ratios

30 years of market, efficiency and balance-sheet ratios

→

Valuation

DCF intrinsic value, peer multiples & estimates

→

IDEXX Laboratories, Inc.(IDXX)Earnings, Financials & Key Ratios

IDXX Key Insights

✓Strengths

✗Weaknesses

IDXX Price & Volume

IDXX Growth Metrics

Revenue CAGR

Profit CAGR

EPS CAGR

Return on Capital

IDXX Recent Earnings

IDXX Peer Comparison

Compare IDXX vs Peers

vs ZTS

vs TMO

Compare Top 5

IDXX Income Statement

IDXX Balance Sheet

IDXX Cash Flow Statement

IDXX Key Ratios

IDXX SEC Filings & Documents

8-K Announcements

10-K Annual Reports

10-Q Quarterly Reports

IDXX Frequently Asked Questions

Explore More IDXX

Full IDXX Stock Analysis

Total Return Calculator

DCA Calculator

Dividend History

Earnings History

Price History

Revenue History

Financial Ratios

Valuation